Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
390 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Crohn's Disease - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Crohn's Disease - Pipeline Review, H2 2014', provides an overview of the Crohn's Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Crohn's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Crohn's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Crohn's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Crohn's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 11 Introduction 12 Global Markets Direct Report Coverage 12 Crohn's Disease Overview 13 Therapeutics Development 14 Pipeline Products for Crohn's Disease - Overview 14 Pipeline Products for Crohn's Disease - Comparative Analysis 15 Crohn's Disease - Therapeutics under Development by Companies 16 Crohn's Disease - Therapeutics under Investigation by Universities/Institutes 24 Crohn's Disease - Pipeline Products Glance 25 Late Stage Products 25 Clinical Stage Products 26 Early Stage Products 27 Unknown Stage Products 28 Crohn's Disease - Products under Development by Companies 29 Crohn's Disease - Products under Investigation by Universities/Institutes 37 Crohn's Disease - Companies Involved in Therapeutics Development 38 4SC AG 38 AB Science 39 AbbVie Inc. 40 Alba Therapeutics Corporation 41 Alfa Wassermann S.p.A 42 Allozyne, Inc. 43 AlphaMab Co., Ltd 44 Amgen Inc. 46 Ampio Pharmaceuticals, Inc. 47 Amunix, Inc. 48 AstraZeneca PLC 49 Biocon Limited 50 BioLineRx, Ltd. 51 Boehringer Ingelheim GmbH 52 Bristol-Myers Squibb Company 53 Calypso Biotech SA 54 Celgene Corporation 55 Celltrion, Inc. 56 ChemoCentryx, Inc. 57 ChironWells GmbH 58 CIMAB S.A. 59 CLL Pharma 60 Daiichi Sankyo Company, Limited 61 DBV Technologies SA 62 Delenex Therapeutics AG 63 Effimune SAS 64 Eisai Co., Ltd. 65 Eli Lilly and Company 66 Emergent BioSolutions Inc. 67 Enlivex Therapeutics Ltd 68 Enzo Biochem, Inc. 69 Epirus Biopharmaceuticals, Inc. 70 Farmacija d.o.o. Tuzla 71 Ferring International Center S.A. 72 Galapagos NV 73 Genfit SA 74 Genor BioPharma Co., Ltd. 75 Gilead Sciences, Inc. 76 GT Biologics Limited 77 iCo Therapeutics Inc. 78 Immune Response BioPharma, Inc. 79 Immunotherapix SAS 80 Inbiopro Solutions Pvt. Ltd. 81 InflammatoRx inc. 82 Innovent Biologics, Inc. 83 Innovimmune Biotherapeutics, Inc. 84 Inovio Pharmaceuticals, Inc. 85 Johnson & Johnson 86 Kangstem Holdings Co., Ltd. 87 Kyorin Pharmaceutical Co., Ltd. 88 Medestea Research & Production S.p.A. 89 Mesoblast Limited 90 Mitsubishi Tanabe Pharma Corporation 91 Neovacs SA 92 Novo Nordisk A/S 93 Oncobiologics, Inc. 94 Oncodesign SA 95 Pfizer Inc. 96 Pieris AG 97 Pluristem Therapeutics Inc. 98 Protalix BioTherapeutics, Inc. 99 Qu Biologics Inc. 100 RedHill Biopharma Ltd. 101 S.L.A. Pharma AG 102 Sandoz Inc. 103 Sanofi 104 Selexys Pharmaceuticals Corporation 105 Sigmoid Pharma Limited 106 Soligenix, Inc. 107 Stelic Institute & Co. 108 Sylentis S.A. 109 Takeda Pharmaceutical Company Limited 110 Teva Pharmaceutical Industries Limited 111 Tillotts Pharma AG 112 Toray Industries, Inc. 113 Trino Therapeutics Ltd 114 TxCell SA 115 Virobay Inc. 116 Winston Pharmaceuticals, Inc. 117 Crohn's Disease - Therapeutics Assessment 118 Assessment by Monotherapy Products 118 Assessment by Combination Products 119 Assessment by Target 120 Assessment by Mechanism of Action 124 Assessment by Route of Administration 128 Assessment by Molecule Type 130 Drug Profiles 132 (mesalamine + N-acetylcysteine) - Drug Profile 132 (metenkefalin + tridecactide) - Drug Profile 134 (rifabutin + clarithromycin + clofazimine) - Drug Profile 135 AB-0045 - Drug Profile 137 abrilumab - Drug Profile 138 ABS-11 - Drug Profile 140 adalimumab - Drug Profile 141 adalimumab biosimilar - Drug Profile 143 adalimumab biosimilar - Drug Profile 144 adalimumab biosimilar - Drug Profile 146 adalimumab biosimilar - Drug Profile 147 adalimumab biosimilar - Drug Profile 148 adalimumab biosimilar - Drug Profile 149 adalimumab biosimilar - Drug Profile 150 adalimumab biosimilar - Drug Profile 151 adalimumab biosimilar - Drug Profile 152 adalimumab biosimilar - Drug Profile 153 Alequel - Drug Profile 154 AMG-139 - Drug Profile 155 Ampion - Drug Profile 156 AMX-256 - Drug Profile 158 Anti-S100A9 Monoclonal Antibody - Drug Profile 159 Antibodies to Inhibit MMP-2 and MMP-9 for Immunology and Gastrointestinal Disorders - Drug Profile 160 Antibodies to Target Metallothioneins for Ulcerative Colitis and Crohns Disease - Drug Profile 161 ApoCell - Drug Profile 162 apremilast - Drug Profile 163 Atrosab - Drug Profile 165 AZ-17 - Drug Profile 166 bertilimumab - Drug Profile 167 BI-655066 - Drug Profile 169 Biologic for Crohn's Disease - Drug Profile 170 BL-5040 - Drug Profile 171 budesonide ER - Drug Profile 172 CALY-001 - Drug Profile 174 cenplacel-L - Drug Profile 175 cyclosporine - Drug Profile 177 Dendritic Cell Therapy for Crohn's Disease - Drug Profile 178 DLX-105 - Drug Profile 179 Drug for Crohn's Disease - Drug Profile 181 Drugs to Inhibit TNFR25 for Gastrointestinal Disorders - Drug Profile 182 E-6011 - Drug Profile 183 eldelumab - Drug Profile 184 ES-210 - Drug Profile 186 etanercept biosimilar - Drug Profile 187 ETX-201 - Drug Profile 188 FE-999301 - Drug Profile 189 FFP-102 - Drug Profile 190 filgotinib - Drug Profile 191 Furestem-CD - Drug Profile 193 GED-0301 - Drug Profile 194 GFT-505 - Drug Profile 195 IAC VITA - Drug Profile 198 IBI-303 - Drug Profile 200 IBPM-004AM - Drug Profile 201 IBPM-005IX - Drug Profile 202 infliximab - Drug Profile 203 infliximab biosimilar - Drug Profile 205 infliximab biosimilar - Drug Profile 207 infliximab biosimilar - Drug Profile 208 INV-88 - Drug Profile 209 IR-777 - Drug Profile 210 ITP-01 - Drug Profile 211 JKB-122 - Drug Profile 212 JNJ-40346527 - Drug Profile 214 KRP-203 - Drug Profile 216 larazotide acetate - Drug Profile 218 LBP-001 - Drug Profile 220 Leukothera - Drug Profile 221 masitinib - Drug Profile 222 mercaptopurine DR - Drug Profile 225 mesalamine CR - Drug Profile 226 metronidazole - Drug Profile 227 MLN-3126 - Drug Profile 229 Monoclonal Antibody to Inhibit TNF Alpha for Crohns Disease and Rheumatoid Arthritis - Drug Profile 230 MP-196 - Drug Profile 231 MT-1303 - Drug Profile 232 naltrexone - Drug Profile 233 naltrexone - Drug Profile 234 NAT-100 - Drug Profile 235 NN-8555 - Drug Profile 236 NN-8828 - Drug Profile 237 ONS-3015 - Drug Profile 239 Ova-Treg - Drug Profile 240 Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease - Drug Profile 242 PF-00547659 - Drug Profile 243 PF-04236921 - Drug Profile 245 PF-06480605 - Drug Profile 246 PH-44 - Drug Profile 247 PH-46A - Drug Profile 248 PH-5 - Drug Profile 249 PRS-190 - Drug Profile 250 QBECO - Drug Profile 251 remestemcel-L - Drug Profile 253 rifaximin - Drug Profile 255 rifaximin DR - Drug Profile 257 RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile 258 SAR-252067 - Drug Profile 259 SelK-2 - Drug Profile 260 SGX-203 - Drug Profile 261 Small Molecule to Agonize OP3 Receptor for Inflammatory Bowel Diseases - Drug Profile 262 Small Molecules for Gastrointestinal Disorders - Drug Profile 263 Small Molecules to Inhibit RIP2 for Crohn's Disease and Polyarthritis - Drug Profile 264 SQ-641 - Drug Profile 265 Stem Cell Therapy for Crohn's Disease - Drug Profile 266 Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile 267 STNM-01 - Drug Profile 268 SYN-1002 - Drug Profile 269 TNF-Kinoid - Drug Profile 270 tofacitinib - Drug Profile 272 TRK-170 - Drug Profile 276 ustekinumab - Drug Profile 277 VBY-036 - Drug Profile 280 vedolizumab - Drug Profile 281 vercirnon sodium - Drug Profile 283 VGX-1027 - Drug Profile 285 vidofludimus - Drug Profile 286 zucapsaicin - Drug Profile 290 Crohn's Disease - Recent Pipeline Updates 292 Crohn's Disease - Dormant Projects 367 Crohn's Disease - Discontinued Products 371 Crohn's Disease - Product Development Milestones 372 Featured News & Press Releases 372 Appendix 381 Methodology 381 Coverage 381 Secondary Research 381 Primary Research 381 Expert Panel Validation 381 Contact Us 382 Disclaimer 382
List of Tables Number of Products under Development for Crohn's Disease, H2 2014 22 Number of Products under Development for Crohn's Disease - Comparative Analysis, H2 2014 23 Number of Products under Development by Companies, H2 2014 25 Number of Products under Development by Companies, H2 2014 (Contd..1) 26 Number of Products under Development by Companies, H2 2014 (Contd..2) 27 Number of Products under Development by Companies, H2 2014 (Contd..3) 28 Number of Products under Development by Companies, H2 2014 (Contd..4) 29 Number of Products under Development by Companies, H2 2014 (Contd..5) 30 Number of Products under Development by Companies, H2 2014 (Contd..6) 31 Number of Products under Investigation by Universities/Institutes, H2 2014 32 Comparative Analysis by Late Stage Development, H2 2014 33 Comparative Analysis by Clinical Stage Development, H2 2014 34 Comparative Analysis by Early Stage Development, H2 2014 35 Comparative Analysis by Unknown Stage Development, H2 2014 36 Products under Development by Companies, H2 2014 37 Products under Development by Companies, H2 2014 (Contd..1) 38 Products under Development by Companies, H2 2014 (Contd..2) 39 Products under Development by Companies, H2 2014 (Contd..3) 40 Products under Development by Companies, H2 2014 (Contd..4) 41 Products under Development by Companies, H2 2014 (Contd..5) 42 Products under Development by Companies, H2 2014 (Contd..6) 43 Products under Development by Companies, H2 2014 (Contd..7) 44 Products under Investigation by Universities/Institutes, H2 2014 45 Crohn's Disease - Pipeline by 4SC AG, H2 2014 46 Crohn's Disease - Pipeline by AB Science, H2 2014 47 Crohn's Disease - Pipeline by AbbVie Inc., H2 2014 48 Crohn's Disease - Pipeline by Alba Therapeutics Corporation, H2 2014 49 Crohn's Disease - Pipeline by Alfa Wassermann S.p.A, H2 2014 50 Crohn's Disease - Pipeline by Allozyne, Inc., H2 2014 51 Crohn's Disease - Pipeline by AlphaMab Co., Ltd, H2 2014 52 Crohn's Disease - Pipeline by Altheus Therapeutics, Inc., H2 2014 53 Crohn's Disease - Pipeline by Amgen Inc., H2 2014 54 Crohn's Disease - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 55 Crohn's Disease - Pipeline by Amunix, Inc., H2 2014 56 Crohn's Disease - Pipeline by AstraZeneca PLC, H2 2014 57 Crohn's Disease - Pipeline by Biocon Limited, H2 2014 58 Crohn's Disease - Pipeline by BioLineRx, Ltd., H2 2014 59 Crohn's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2014 60 Crohn's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2014 61 Crohn's Disease - Pipeline by Calypso Biotech SA, H2 2014 62 Crohn's Disease - Pipeline by Celgene Corporation, H2 2014 63 Crohn's Disease - Pipeline by Celltrion, Inc., H2 2014 64 Crohn's Disease - Pipeline by ChemoCentryx, Inc., H2 2014 65 Crohn's Disease - Pipeline by ChironWells GmbH, H2 2014 66 Crohn's Disease - Pipeline by CIMAB S.A., H2 2014 67 Crohn's Disease - Pipeline by CLL Pharma, H2 2014 68 Crohn's Disease - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 69 Crohn's Disease - Pipeline by DBV Technologies SA, H2 2014 70 Crohn's Disease - Pipeline by Delenex Therapeutics AG, H2 2014 71 Crohn's Disease - Pipeline by Effimune SAS, H2 2014 72 Crohn's Disease - Pipeline by Eisai Co., Ltd., H2 2014 73 Crohn's Disease - Pipeline by Eli Lilly and Company, H2 2014 74 Crohn's Disease - Pipeline by Emergent BioSolutions Inc., H2 2014 75 Crohn's Disease - Pipeline by Enlivex Therapeutics Ltd, H2 2014 76 Crohn's Disease - Pipeline by Enzo Biochem, Inc., H2 2014 77 Crohn's Disease - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 78 Crohn's Disease - Pipeline by Farmacija d.o.o. Tuzla, H2 2014 79 Crohn's Disease - Pipeline by Ferring International Center S.A., H2 2014 80 Crohn's Disease - Pipeline by Galapagos NV, H2 2014 81 Crohn's Disease - Pipeline by Genfit SA, H2 2014 82 Crohn's Disease - Pipeline by Genor BioPharma Co., Ltd., H2 2014 83 Crohn's Disease - Pipeline by Gilead Sciences, Inc., H2 2014 84 Crohn's Disease - Pipeline by GT Biologics Limited, H2 2014 85 Crohn's Disease - Pipeline by iCo Therapeutics Inc., H2 2014 86 Crohn's Disease - Pipeline by Immune Response BioPharma, Inc., H2 2014 87 Crohn's Disease - Pipeline by Immunotherapix SAS, H2 2014 88 Crohn's Disease - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 89 Crohn's Disease - Pipeline by InflammatoRx inc., H2 2014 90 Crohn's Disease - Pipeline by Innovent Biologics, Inc., H2 2014 91 Crohn's Disease - Pipeline by Innovimmune Biotherapeutics, Inc., H2 2014 92 Crohn's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 93 Crohn's Disease - Pipeline by Johnson & Johnson, H2 2014 94 Crohn's Disease - Pipeline by Kangstem Holdings Co., Ltd., H2 2014 95 Crohn's Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 96 Crohn's Disease - Pipeline by Medestea Research & Production S.p.A., H2 2014 97 Crohn's Disease - Pipeline by Mesoblast Limited, H2 2014 98 Crohn's Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 99 Crohn's Disease - Pipeline by Neovacs SA, H2 2014 100 Crohn's Disease - Pipeline by Novo Nordisk A/S, H2 2014 101 Crohn's Disease - Pipeline by Oncobiologics, Inc., H2 2014 102 Crohn's Disease - Pipeline by Oncodesign SA, H2 2014 103 Crohn's Disease - Pipeline by Pfizer Inc., H2 2014 104 Crohn's Disease - Pipeline by Pieris AG, H2 2014 105 Crohn's Disease - Pipeline by Pluristem Therapeutics Inc., H2 2014 106 Crohn's Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 107 Crohn's Disease - Pipeline by Qu Biologics Inc., H2 2014 108 Crohn's Disease - Pipeline by RedHill Biopharma Ltd., H2 2014 109 Crohn's Disease - Pipeline by S.L.A. Pharma AG, H2 2014 110 Crohn's Disease - Pipeline by Sandoz Inc., H2 2014 111 Crohn's Disease - Pipeline by Sanofi, H2 2014 112 Crohn's Disease - Pipeline by Selexys Pharmaceuticals Corporation, H2 2014 113 Crohn's Disease - Pipeline by Sigmoid Pharma Limited, H2 2014 114 Crohn's Disease - Pipeline by Soligenix, Inc., H2 2014 115 Crohn's Disease - Pipeline by Stelic Institute & Co., H2 2014 116 Crohn's Disease - Pipeline by Sylentis S.A., H2 2014 117 Crohn's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 118 Crohn's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 119 Crohn's Disease - Pipeline by Tillotts Pharma AG, H2 2014 120 Crohn's Disease - Pipeline by Toray Industries, Inc., H2 2014 121 Crohn's Disease - Pipeline by Trino Therapeutics Ltd, H2 2014 122 Crohn's Disease - Pipeline by TxCell SA, H2 2014 123 Crohn's Disease - Pipeline by Virobay Inc., H2 2014 124 Crohn's Disease - Pipeline by Winston Pharmaceuticals, Inc., H2 2014 125 Assessment by Monotherapy Products, H2 2014 126 Assessment by Combination Products, H2 2014 127 Number of Products by Stage and Target, H2 2014 129 Number of Products by Stage and Mechanism of Action, H2 2014 133 Number of Products by Stage and Route of Administration, H2 2014 137 Number of Products by Stage and Molecule Type, H2 2014 139 Crohn's Disease Therapeutics - Recent Pipeline Updates, H2 2014 300 Crohn's Disease - Dormant Projects, H2 2014 375 Crohn's Disease - Discontinued Products, H2 2014 379
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
